Vimizim 2021 U.S. PROMOTIONAL AUDIT REPORT

Published July 2022 • 24 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Vimizim through reportable promotional activity in 2021 to drive use within the Mucopolysaccharidosis Type IV market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does BioMarin’s depth of coverage vary within key specialties (e.g., Orthopedic Surgery, Nursing, Medical Genetics, Pediatric Medicine, and Physician Assistant) and how does this compare to the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Vimizim throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Vimizim in 2021?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 150 paid interactions across 110 physicians made on behalf of Vimizim were carefully examined to support our analysis.